Interleukin-23 Inhibitors
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab. Response to treatment should be evaluated after a 12-week treatment period in psoriasis pati...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Publishing House
2022-04-01
|
Series: | Turkderm Turkish Archives of Dermatology and Venereology |
Subjects: | |
Online Access: | https://journal.turkderm.org.tr/jvi.aspx?pdir=turkderm&plng=eng&un=TURKDERM-06337&look4= |